Osteoporosis

Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women

Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women

By

Romosozumab increased bone mineral density in postmenopausal women through increased bone formation and decreased bone resorption.

Examining Bone Microarchitecture, Strength in Older Men With Accelerated Bone Loss

Examining Bone Microarchitecture, Strength in Older Men With Accelerated Bone Loss

By

Men with accelerated bone loss have lower estimated bone strength, poorer trabecular microarchitecture, and thinner cortices compared with men without accelerated bone loss.

Good Glycemic Control May Influence Bone Metabolism in Type 2 Diabetes

Good Glycemic Control May Influence Bone Metabolism in Type 2 Diabetes

By

Researchers showed that improved glycemic control is associated with higher bone resorption, possibly reflecting normalization rather than an abnormal increase in bone resorption.

USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention

USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention

By

The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.

Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis

Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis

By

Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.

Low Sperm Count Linked to Poor Metabolic, Cardiovascular, Bone Health

Low Sperm Count Linked to Poor Metabolic, Cardiovascular, Bone Health

By

Researchers tested whether semen quality and reproductive function could be a marker of general health in men.

Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures

Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures

By

Roux-en Y gastric bypass increased the likelihood of nonvertebral fractures, including hip, wrist, and pelvic fractures.

Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome

Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome

By

Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.

Osteoporotic Fracture Risk Predicted by Vertebral Trabecular Attenuation on Routine CT

Osteoporotic Fracture Risk Predicted by Vertebral Trabecular Attenuation on Routine CT

By

Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.

Romosozumab Followed by Alendronate Decreases Fracture Risk in Women With Osteoporosis

Romosozumab Followed by Alendronate Decreases Fracture Risk in Women With Osteoporosis

By

In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.

Fracture Risk in Postmenopausal Women With Osteoporosis May Improve With Growth Hormone Therapy

Fracture Risk in Postmenopausal Women With Osteoporosis May Improve With Growth Hormone Therapy

By

A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.

Teriparatide More Effective Than Risedronate in Osteoporotic Fractures

Teriparatide More Effective Than Risedronate in Osteoporotic Fractures

By

Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.

Prolonged Antiresorptive Activity With Zoledronate in Postmenopausal Osteopenia

Prolonged Antiresorptive Activity With Zoledronate in Postmenopausal Osteopenia

In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.

Risks Associated With Denosumab Discontinuation

Risks Associated With Denosumab Discontinuation

Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.

Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk

Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk

By

The USPSTF commissioned a systematic evidence review on vitamin D, calcium, and combined supplementation for the primary prevention of fractures in community-dwelling adults.

Managing Osteoporosis With Type 2 Diabetes: An Expert Opinion

Managing Osteoporosis With Type 2 Diabetes: An Expert Opinion

By

Researchers conducted a systematic review of available literature to create a guide for optimal management of patients with type 2 diabetes and osteoporosis.

FDA Requests Additional Data in Romosozumab Biologics License Application

FDA Requests Additional Data in Romosozumab Biologics License Application

By

The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.

Does Sedative Use Increase Repeat Fall Risk?

Does Sedative Use Increase Repeat Fall Risk?

By

Daytime sleepiness and poor quality of sleep affect recurrent fall risk in the elderly.

ACP: Updated Osteoporosis Treatment Guidelines

ACP: Updated Osteoporosis Treatment Guidelines

By

An update to the 2008 ACP osteoporosis treatment guidelines focuses on treating low bone density and osteoporosis in an effort to prevent fractures.

Osteoporosis, Fracture Risk Elevated With Tuberculosis

Osteoporosis, Fracture Risk Elevated With Tuberculosis

By

Tuberculosis was identified as an independent risk factor associated with incident osteoporosis.

Osteoporosis Treatment Approaches in Women vs Men

Osteoporosis Treatment Approaches in Women vs Men

By

A review of osteoporosis diagnosis, treatment, and management in both men and women.

Benefits of Osteoporosis Pharmacotherapy Misunderstood Among Older Women

Benefits of Osteoporosis Pharmacotherapy Misunderstood Among Older Women

Eighty-four percent of survey respondents did not undergo osteoporosis pharmacotherapy following an osteoporosis-related fracture.

FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With Osteoporosis

FDA Approves Abaloparatide for Fragility Fracture in Postmenopausal Women With Osteoporosis

By

Tymlos approval was based on the results of the ACTIVE and ACTIVExtension trials.

HIV-Induced Osteoporosis Detected Using Bone Ultrasonography

HIV-Induced Osteoporosis Detected Using Bone Ultrasonography

By

Bone ultrasonography is able to detect tenofovir-induced bone loss in patients with HIV.

Denosumab-induced Prolonged Hypocalcemia: A Case Study

Denosumab-induced Prolonged Hypocalcemia: A Case Study

By

Investigators examined an 83-year-old male patient who developed severe hypocalcemia induced by denosumab.

Long-Term Safety of Denosumab in Postmenopausal Osteoperosis

Long-Term Safety of Denosumab in Postmenopausal Osteoperosis

By

The most common adverse events associated with long-term denosumab use were back, musculoskeletal, or extremity pain, hypercholesterolemia, and cystis.

Osteoporosis Care Quality Most Consistently Predicted By Primary Care

Osteoporosis Care Quality Most Consistently Predicted By Primary Care

By

The most important predictor for use of osteoporosis care was receiving primary care services within 6 months following hip fracture.

DXA-Visceral Adipose Tissue Measurements in Atherosclerotic CVD Risk Assessment

DXA-Visceral Adipose Tissue Measurements in Atherosclerotic CVD Risk Assessment

By

Neither DXA-visceral adipose tissue nor android-gynoid fat mass ratios were associated with atherosclerotic cardiovascular disease events.

Leg Positioning During Lumbar Spine DXA

Leg Positioning During Lumbar Spine DXA

By

Researchers evaluated trabecular bone scores in more than 100 women during either "legs up" or "legs down" dual energy x-ray absorptiometry scans.

Sign Up for Free e-Newsletters



CME Focus